Evidence map›Paper›PMID 37859307›Full record

ArticleCurrent neuropharmacology2024

Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study.

Zhiyong Gao, Meihong Xiu, Jiahong Liu, Fengchun Wu, Xiangyang Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current neuropharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Zhiyong GaoThe Affiliated Kangning Hospital of Wenzhou Medical University Zhejiang Provincial Clinical Research Center for Mental Disorder, Wenzhou, China.
Meihong XiuPeking University Huilongguan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Jiahong LiuThe Affiliated Kangning Hospital of Wenzhou Medical University Zhejiang Provincial Clinical Research Center for Mental Disorder, Wenzhou, China.
Fengchun WuDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Xiangyang ZhangDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Guangzhou Medical University · CNWenzhou Medical University · CNPeking University · CN

Funding

Guangdong Basic and Applied Basic Research Foundation Outstanding Youth Project 2021B1515020064Health Science and Technology Program of Guangzhou 20231A010036Medical Science and Technology Research Foundation of Guangdong A2023224Science and Technology Program of Guangzhou 202206060005, 202201010093, SL2022A03J01489Scientific research project of traditional Chinese medicine of Guangdong 20211306
6 · The paper itself

Abstract

backgroundIt has been hypothesized that smoking is associated with the severity of negative symptoms. Until now, no studies have investigated whether the impact of smoking on negative symptoms is dependent on antioxidants. This study was designed to evaluate the effect of smoking on therapeutic response and total antioxidants capacity (TAOC) in antipsychotic-naïve first-episode (ANFE) patients.

methodsThe severity of the patient's symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS). A total of 237 ANFE patients were recruited and treated with risperidone (oral tablets, 4-6 mg/day twice a day) for 12 weeks. PANSS was assessed at baseline and a 12-week follow-up. Plasma TAOC levels were also assayed at baseline and week 12.

resultsRelative to nonsmokers with ANFE SZ, smokers had higher PANSS negative subscores. There was no significant difference in TAOC changes after 12 weeks of treatment with risperidone between smokers and non-smokers. However, we found greater improvement in negative symptoms in smokers compared to non-smokers. Further analysis in smokers with SZ demonstrated that improvements in negative symptoms were not associated with changes in TAOC.

conclusionOur study suggested that smoking affected the severity of baseline negative symptoms and further contributed to their reduction after risperidone treatment. However, improvement in negative symptoms was not dependent on the changes in TAOC.

Indexed as

AntioxidantsAntipsychotic AgentsRisperidoneSchizophreniaSmokingAdolescentAdultCohort StudiesFemaleHumansMaleProspective StudiesPsychiatric Status Rating ScalesSchizophrenic PsychologyTreatment OutcomeYoung AdultAntioxidantsAntipsychotic AgentsRisperidoneANFEPANSS.risperidoneSchizophreniasmokingtotal antioxidant capacity

Identifiers

PMID37859307
PMCPMC11284715
OpenAlexW4387780574

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.